Showing 8121-8130 of 10143 results for "".
- Arcutis Launches Educational Campaign for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-educational-campaign-for-people-living-with-seborrheic-dermatitis/2462021/Arcutis Biotherapeutics, Inc. is launching
- UCB Anticipates Delay for FDA Bimekizumab Decisionhttps://practicaldermatology.com/news/ucb-anticipates-delay-for-fda-bimekizumab-decision/2462017/The anticipated Biologics License Application (BLA) for bimekizumab to treat plaque psoriasis will likely be delayed beyond Q3 2023, according to a statement from UCB. Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) an
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to est
- A Livestock Drug Delivered Via Nanoparticles May Help Eradicate Acnehttps://practicaldermatology.com/news/a-livestock-drug-delivered-via-nanoparticles-may-help-eradicate-acne/2462004/Australian scientists may have found an effective treatment for acne that is delivered via tiny nanoparticles. In a study led by the
- Interim INTEGUMENT-OLE Results: Arcutis’ Roflumilast Cream 0.15% Performs Well in ADhttps://practicaldermatology.com/news/arcutis-roflumilast-cream-015-performs-well-in-ad/2461987/Roflumilast cream 0.15% showed durable and improved efficacy over time and a favorable safety profile in mild to moderate Atopic Dermatitis (AD), according to interim results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental New Drug Applicatio
- Melanoma Discovery: Understanding the Role of GREB1 Isoform4 in Melanomahttps://practicaldermatology.com/news/melanoma-discovery-understanding-the-role-of-greb1-isoform4-in-melanoma/2461979/GREB1 Isoform4 (Is4) is involved in pyrimidine synthesis and causes malignant melanoma, suggesting GREB1 Is4 a new therapeutic target for melanoma, according to a study in Oncogene. The expression of a specif
- AbbVie Awards 45 Scholarships to U.S. Students Living With Psoriasis, Eczema, and Other Chronic, Immune-Mediated Diseaseshttps://practicaldermatology.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-psoriasis-eczema-and-other-chronic-immune-mediated-diseases/2461970/AbbVie announced the 2023-2024 class of
- New App-controlled Device May Help Quickly Identify Infected Woundshttps://practicaldermatology.com/news/new-app-controlled-device-may-help-quickly-identify-infected-wounds/2461959/A new app-controlled device may allow doctors to spot infected wounds faster. The scientists developed a device called the Swift Ray 1 which can be attached to a smartphone and connected to the Swift Skin and Wound software. It can take medical-grade photographs, inf
- The Dermatology Foundation, Skin of Color Society Partner to Offer Sanofi-Regeneron DEI Mid-Career Awardhttps://practicaldermatology.com/news/the-dermatology-foundation-skin-of-color-society-partner-to-offer-sanofi-regeneron-dei-mid-career-award/2461952/The Dermatology Foundation (DF) and the
- Conagen Introduces Novel Natural-source Retinol for Cosmetic Formulationshttps://practicaldermatology.com/news/conagen-introduces-novel-natural-source-retinol-for-cosmetic-formulations/2461951/